New Treatment Available to New Zealanders Seeking a Viral Cure* for Hepatitis C1
• Up to half of New Zealanders living with hepatitis C don’t know they have the virus4 Wellington, 1 February 2019 – AbbVie (NYSE: ABBV) New Zealand today announced MAVIRET® (glecaprevir/pibrentasvir) is
now available and fully funded by PHARMAC, giving New Zealanders living with all major genotypes of hepatitis C access
to a high certainty of viral cure*1.
MAVIRET® is a new, once-daily tablet treatment for adults with any major genotype of hepatitis C. Most people will only
need to take MAVIRET for eight weeks5. The therapy contains two direct-acting anti-viral agents that work to block the
lifecycle of the hepatitis C virus in a patient. Doctors consider a patient virologically cured of hepatitis C if the
patient has undetectable levels of the virus 12 weeks after completing the treatment course.
There could be an estimated 50,000 New Zealanders living with hepatitis C and approximately 1,000 new infections every
year2,4. Left untreated, hepatitis C can cause cirrhosis, liver failure and liver cancer3.
Professor Ed Gane, chief hepatologist, transplant physician and deputy director of the New Zealand Liver Transplant
Unit at Auckland City Hospital said: “Chronic hepatitis C is an important cause of liver failure, liver cancer and
liver-related deaths in New Zealand4. With early diagnosis and new treatments we could prevent hepatitis C-related
illness and death in New Zealand4.
“The funding of new treatments takes New Zealand one step closer to eliminating hepatitis C as a public health threat
and reaching the World Health Organisation target of global elimination of hepatitis C by 2030,” he said.
Andrew Tompkin, General Manager AbbVie New Zealand said the funding of MAVIRET® would have a positive impact on the
lives of many New Zealanders living with hepatitis C6, offering them a high certainty of cure from the virus*.
“We have seen significant medical advancements in the development of hepatitis C medicines from the initial discovery
of the virus in the 1980s, to the development and commercialisation of today’s direct-acting antivirals, which provide
an opportunity to eliminate the disease in New Zealand within a generation.
“This new treatment option will mean more New Zealanders living with hepatitis C can be successfully treated.
“AbbVie is committed to helping eliminate hepatitis C by providing treatment options and supporting community
elimination programmes across the world,” he said.
All medicines have adverse effects and may impact different people in different ways. In clinical trials with MAVIRET®,
the most common adverse effects were mild in nature and included feeling tired, headache and nausea. Refer to the
Consumer Medicines Information or your doctor or pharmacist for further information about MAVIRET®.
New Zealanders with hepatitis C are encouraged to see their doctor to have their liver health assessed and to discuss
treatment options.
ends